Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3348877 | 0.95 | TP53 (0.41) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL3343293 | 0.80 | PARP1 (0.46) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL5640727 | 0.73 | PARP1 (0.43) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL4800639 | 0.69 | PARP1 (0.51) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL4799215 | 0.69 | PARP1 (0.51) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL3342730 | 0.68 | TP53 (0.41) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL3345231 | 0.68 | KDM1A (0.44) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL3342732 | 0.66 | TP53 (0.41) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL3346129 | 0.66 | PARP1 (0.56) | TP53MAPTTHRBALDH1A1HSD17B10 | |
| SCHEMBL14367228 | 0.66 | PARP1 (0.56) | TP53MAPTTHRBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858776-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2010-12-28 | — | — | US | disclosed |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-7294622-B2 | Lactams and uses thereof | ASTRAZENECA AB (SE) | 2007-11-13 | — | — | US | disclosed |
| EP-1845089-A1 | Novel lactams and uses thereof | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-7183296-B2 | Anti-HIV pyrazole derivatives | ROCHE PALO ALTO LLC (US) | 2007-02-27 | — | — | US | disclosed |
| US-20060089346-A1 | Novel lactams and uses thereof | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| US-20040192752-A1 | Anti-HIV pyrazole derivatives | DYMOCK BRIAN WILLIAM (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192752-A1 | Anti-HIV pyrazole derivatives | CYP51A1, TYMP, POLRMT | TP53 3502/4885MAPT 2148/4885THRB 3817/4885 |
| US-20060089346-A1 | Novel lactams and uses thereof | BACE1, BACE2, APH1B | TP53 4815/4885MAPT 23/4885THRB 1543/4885 |
| US-20080076752-A1 | substituted structure of 3-amino-2-(2,5-difluorophenyl)-2,3-dihydro-1,5-benzothiazepin-4(5H)-one; 6-amino-7-phenyl-1,4-thiazepan-5-one; -amino-2-phenyl-2,3-dihydro-1,5-benzoxazepin-4(5H)-one for treating neurological disorders such as Alzheimer's; inhibit the production of amyloid beta protein | APP, BACE1, PSEN1 | TP53 4478/4885MAPT 24/4885THRB 1738/4885 |
| US-20100160627-A1 | NOVEL LACTAMS AND USES THEREOF | BACE1, BACE2, APP | TP53 4810/4885MAPT 24/4885THRB 1890/4885 |
| US-20090054398-A1 | CHEMICAL COMPOUNDS | NOTCH1, HES1, NOTCH2 | TP53 243/4885MAPT 1368/4885THRB 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.